Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps
CTR20250539Phase 3Active
- Sponsor
- Sanofi
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of itepekimab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Sanofi. Started Mar 2025; status: active.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20250539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250539.